This company develops and manufactures active pharmaceutical ingredients (APIs) like high-potency peptides and anti-cancer drugs, along with corresponding injectable formulations. They also offer contract development and manufacturing organization (CDMO) services, providing outsourced pharmaceutical R&D and manufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical companies face challenges in sourcing high-quality, high-potency active pharmaceutical ingredients (APIs) and corresponding injectable formulations, especially for peptides and anti-cancer drugs. Outsourcing R&D and manufacturing can be complex, requiring a contract development and manufacturing organization (CDMO) with specialized expertise and facilities.
Solution
Genohope Biotech is a contract development and manufacturing organization (CDMO) specializing in the production of high-potency APIs, including peptides and anti-cancer drugs, as well as injectable formulations. The company offers comprehensive services, from early-stage research and development to GMP-compliant manufacturing, supporting pharmaceutical companies in bringing innovative therapies to market. Genohope Biotech leverages advanced technologies, such as solid-phase synthesis and recombinant fermentation, to produce APIs with high purity and yield. With multiple production lines and a quality control center, the company ensures adherence to global regulatory standards, including US FDA requirements.
Target Audience
Genohope Biotech serves pharmaceutical companies globally, focusing on those requiring high-quality APIs, injectable formulations, and outsourced R&D and manufacturing services, particularly in the diabetes, obesity, and oncology therapeutic areas.
Features
- Manufacturing of high-potency APIs, including GLP-1 receptor agonists like Semaglutide, Tirzepatide, and Liraglutide
- Production of injectable formulations, including lyophilized powder and water injections, prefilled syringes, and prefilled cartridge injections
- Solid-phase synthesis reactors with up to 2000L capacity for peptide API synthesis
- Biotechnology fermentation production line with microbial culture equipment ranging from 8000L to 300000L
- Purification equipment including AKTAready liquid chromatography systems and medium pressure preparative chromatography (MPLC)
- Ultrafiltration equipment utilizing Tangential Flow Filtration (TFF)
- GMP-compliant production workshops with a total construction area of approximately 70,000 square meters
- US FDA registered Semaglutide API (DMF No. : 040957) and Tirzepatide API (DMF No. : 040503)